Agenda Item: 5.2

JOINT COMMISSIONING COMMITTEE FORWARD PLAN OF BUSINESS TO MARCH 2027

The Joint Commissioning Committee (JC) meets bi-monthly. Based on this, the following table represents a proposal to incorporate the duties as outlined in the NHS Wales Joint Commissioning Committee Standing Orders into a Forward Plan of Business to March 2027.

AGENDA ITEM/ ISSUE	LEAD	24 Nov 2026	19 Jan 2027	23 March 2027
1. PRELIMINARY MATTERS				
Welcome and Apologies	**Chair**	🏳	🏳	🏳
Apologies for Absence				
Declarations of Interests				
Minutes from Previous Meeting				
Matters Arising				
Action Log				
2. SETTING THE SCENE				
Chair's Report	**Chair**	🏳	🏳	🏳
Chief Commissioner's Report including Director of Commissioning Updates	**Chief Commissioner**	🏳	🏳	🏳
2.0 Matters Arising:				

AGENDA ITEM/ ISSUE	LEAD	24 Nov 2026	19 Jan 2027	23 March 2027
3. DELIVERING THE NWJCC PLAN				
NWJCC Financial Performance Report (Monthly Reporting)	**Director of Finance and Value**	⚑	⚑	⚑
NWJCC Performance Report	**Director of Finance and Value**	⚑	⚑	⚑
Annual Plan Delivery Update	**Director of Corporate Planning and Strategy**	⚑	⚑	⚑
NWJCC Integrated Medium Term Plan 2027-2030 (By Exception)	**Director of Corporate Planning and Strategy**	⚑	⚑	⚑
Strategy and Planning Maturity Self-Assessment	**Director of Corporate Planning and Strategy**	⚑		
3.0 Matters Arising				
Strategic Reviews **May –** Set Out Strategic Direction with the JC; consider service specifications for reviews. **September –** Mid-year report on initial findings, assessment and initial recommendations. **January –** Approval of reports and recommendations; consider implementation plan for next phase	**Director of Corporate Planning and Strategy**		⚑	
(Within Annual Plan agenda item) **IPFR Deep Dive** **Cardiac Strategic Review** **Mechanical Thrombectomy Deep Dive**	**Medical Director** **Director of Commissioning for Specialist Services**	⚑		
MH Strategic Review Update	**Director of Commissioning for MH, LD and VG**		⚑	

AGENDA ITEM/ ISSUE	LEAD	24 Nov 2026	19 Jan 2027	23 March 2027
Advanced Therapy Medicinal Product (ATMP) Options Appraisal	**Medical Director**		🏳	
Pathways and Referral Management Present outputs from Phase 2; agreement on proposed approach to SPOA for referral management	**Director of Finance**		🏳	
4. GOVERNANCE, ASSURANCE AND DECISIONS				
Risk Management including JAF and ORR	**Committee Secretary**	🏳	🏳	🏳
Corporate Governance Report	**Committee Secretary**	🏳	🏳	🏳
Sub-Committee Terms of Reference (for onward approval by HBs), Sub-committee Annual Reports	**Committee Secretary**			🏳
JC and Sub-Committee Forward Plan of Business (for onward approval by HBs)	**Committee Secretary**			🏳
Immunoglobulin Update	**Medical Director**		🏳	
Rural Response Options Update	**Director of Commissioning for Ambulance Services and National Programmes**		🏳	
Remote Clinical Assessment Hubs	**Director of Commissioning for Ambulance Services and National Programmes**		🏳	
Recurrent and Non-recurrent Slippage Update (Financial Sustainability)	**Director of Finance and Value**		🏳	
Contract renewal for SE Wales Haemodialysis Units	**Director of Commissioning for Specialised Services**	🏳		
4.0 Matters Arising:				

AGENDA ITEM/ ISSUE	LEAD	24 Nov 2026	19 Jan 2027	23 March 2027
5. FOR INFORMATION				
Highlight Reports from the NWJCC Sub-Committees and Hosted Bodies Audit, Risk and Assurance (ARAC)	**Committee Secretary**	🏳	🏳	🏳
6. CONCLUDING BUSINESS				
Any Other Business	**Chair**	🏳	🏳	🏳
Review of the Meeting				
Date of the next Meeting				